ClinicalTrials.gg
CompletedNCT01181726Updated Dec 8, 2010Results posted

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

A Phase 1 interventional study of Estradiol/Norethindrone acetate and Activella® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-08.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking or smoking (up to 10 cigarettes/day), physiologically or surgically female within the age range of 18-65 years.
  • 17β-estradiol serum levels of ≤ 92 pmol/L and follicle-stimulating hormone (FSH) of ≥ 40 IU/L.
  • (BMI) greater than or equal to 19.0 kg/m2 and less than or equal to 30.0 kg/m2.
  • Normal findings in the physical examination, 12-lead (ECG) and vital signs.
  • ≥ 115 g/L.
  • Normal pap smear.
  • Normal mammogram within 1 year for subjects who are over the age of 50 years.
  • Negative for drugs of abuse and alcohol.
  • Negative for -surface antigen, , and (HIV).
  • No clinical laboratory values outside the acceptable range unless the Principal Investigator or Sub-Investigator decides that they are not (NCS).
  • Negative for pregnancy.
  • Subjects who are surgically post-menopausal with an intact uterus (i.e. bilateral oophorectomy) for at least 6 months, or physiologically post-menopausal (i.e. spontaneous amenorrhea) for at least 1 year, and who will adhere to requirements from at least 10 days before Period I check-in, during the study and up until 1 month after the end of the study.
  • Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF.

Exclusion criteria

Exclusion Criteria:

  • Known history of to norethindrone and estradiol combinations and/or norethindrone, and/or estradiol.
  • Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, or hematological diseases, , or migraines, unless deemed not by the Principal Investigator or Sub-Investigator.
  • Known history of liver, kidney, and/or gallbladder dysfunction/disease, chronic diarrhea, or inflammatory bowel diseases.
  • Known history or presence of cerebrovascular diseases or venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
  • Any history of stroke.
  • Presence of any significant physical or organ abnormality.
  • History of osteoporosis.
  • History or presence of fibrocystic breast disease.
  • History or presence of breast, endometrial, cervical, and/or uterine carcinoma.
  • Any illness during the 4 weeks before this study, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
  • Any history or evidence of psychiatric or psychological disease, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
  • Any history or abnormal vaginal bleeding, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
  • Any history of asthma (after 12 years of age).
  • Evidence of pregnancy or lactation.
  • Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
  • Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • Any history or drug abuse.
  • Any recent history of alcohol abuse (less than 1 year).
  • Use of any prescription medication within 30 days preceding this study.
  • Use of hormone replacement therapy within 30 days before drug administration.
  • Use of over-the-counter (OTC) medication or any herbal supplement within the 7 days preceding this study.
  • Use of hormonal , oral, transdermal, implant within 30 days before drug administration or a depot injection or progestogen drug within 1 year before the drug administration.
  • Depot injection of any drug within 6 months.
  • Blood draws within 56 days preceding this study, during the conduct of any clinical study at another facility, or within the lockout period specified by previous study.
  • Blood donations within 56 days preceding this study.
  • Participation as a plasma donor in a plasmapheresis program within 7 days preceding this study.
  • Participation in a clinical trial with an drug within 30 days preceding this study.
  • Intolerance to venipuncture.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Investigational Test Product

    Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg

    Drug: Estradiol/Norethindrone acetate

  • Active comparator
    Reference Listed Drug

    Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets

    Drug: Activella®

Interventions

  • DrugEstradiol/Norethindrone acetate

    Drug pages: Estradiol · Norethindrone Acetate

    1 mg/0.5 mg Tablets

    Also known as: Mimvey®

  • DrugActivella®

    1 mg/0.5 mg Tablets

    Also known as: Estradiol/Norethindrone acetate (generic name)

06

What researchers measure

Primary outcomes

  1. Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)

    Bioequivalence based on Norethindrone Cmax.

    Time frame: Blood samples collected over a 36 hour period.

  2. AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on Norethindrone AUC0-t.

    Time frame: Blood samples collected over a 36 hour period.

  3. AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on Norethindrone AUC0-inf.

    Time frame: Blood samples collected over a 36 hour period.

  4. Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

    Bioequivalence based on Corrected Total Estrone Cmax.

    Time frame: Blood samples collected over a 72 hour period.

  5. AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on Corrected Total Estrone AUC0-t.

    Time frame: Blood samples collected over a 72 hour period.

  6. AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on Corrected Total Estrone AUC0-inf.

    Time frame: Blood samples collected over a 72 hour period.

Secondary outcomes

  1. Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

    Informational comparison of Cmax values for Uncorrected Total Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  2. AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Informational comparison of AUC0-t values for Uncorrected Total Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  3. AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Informational comparison of AUC0-inf values for Uncorrected Total Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  4. Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

    Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol.

    Time frame: Blood samples collected over a 72 hour period.

  5. AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol.

    Time frame: Blood samples collected over a 72 hour period.

  6. AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol.

    Time frame: Blood samples collected over a 72 hour period.

  7. Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

    Informational comparison of Cmax values for Uncorrected Unconjugated Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  8. AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  9. AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  10. Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

    Informational comparison of Cmax values for Corrected Unconjugated Estradiol.

    Time frame: Blood samples collected over a 72 hour period.

  11. AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol.

    Time frame: Blood samples collected over a 72 hour period.

  12. AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol.

    Time frame: Blood samples collected over a 72 hour period.

  13. Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

    Informational comparison of Cmax values for Corrected Unconjugated Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  14. AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Informational comparison of AUC0-t values for Corrected Unconjugated Estrone.

    Time frame: Blood samples collected over a 72 hour period.

  15. AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

    Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone.

    Time frame: Blood samples collected over a 72 hour period.

07

Results

Posted Oct 7, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneEstradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) First
Started2020
Completed1920
Not completed10
Withdrew: Adverse event10
Washout of 28 Days
Participant flow — Washout of 28 Days
MilestoneEstradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) First
Started1920
Completed1920
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneEstradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) First
Started1920
Completed1920
Not completed00

Outcome measures

PrimaryCmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Norethindrone Cmax.

Time frame:
Blood samples collected over a 36 hour period.
Reported as:
Mean · ng/mL
Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)6.54 ± 3.626.06 ± 2.95
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 104.66 · 90% CI 94.22 to 116.25Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Norethindrone AUC0-t.

Time frame:
Blood samples collected over a 36 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
ng*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)45.03 ± 21.7646.13 ± 21.62
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.4 · 90% CI 93.91 to 101.02Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Norethindrone AUC0-inf.

Time frame:
Blood samples collected over a 36 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
ng*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)49.55 ± 23.0850.68 ± 22.78
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.60 · 90% CI 94.05 to 101.30Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryCmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Corrected Total Estrone Cmax.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg/mL
Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
pg/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)27076.08 ± 11600.1327240.03 ± 11610.70
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 99.35 · 90% CI 92.21 to 107.06Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Corrected Total Estrone AUC0-t.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)384547.68 ± 185543.06407028.98 ± 191192.18
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 95.21 · 90% CI 91.21 to 99.39Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Corrected Total Estrone AUC0-inf.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)380131.12 ± 163543.17424801.99 ± 216597.41
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 95.25 · 90% CI 91.18 to 99.51Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
SecondaryCmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Total Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg/mL
Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
pg/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)27256.41 ± 11652.7827430.77 ± 11674.97
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 99.33 · 90% CI 92.21 to 107.00This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Total Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)397537.88 ± 193337.67420763.02 ± 198975.61
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 95.19 · 90% CI 91.18 to 99.38This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Total Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)398139.63 ± 173723.79425739.45 ± 198546.75
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 95.23 · 90% CI 91.17 to 99.47This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryCmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg/mL
Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
pg/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)59.24 ± 19.1060.33 ± 19.04
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.92 · 90% CI 93.44 to 102.61This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)2016.26 ± 596.402086.39 ± 746.24
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.77 · 90% CI 93.92 to 101.78This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)2301.59 ± 642.092274.04 ± 784.48
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 99.71 · 90% CI 94.42 to 105.30This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryCmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Uncorrected Unconjugated Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg/mL
Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
pg/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)513.56 ± 165.85529.23 ± 217.12
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 99.19 · 90% CI 94.71 to 103.87This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)12444.22 ± 4018.3912977.00 ± 5291.36
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.83 · 90% CI 94.55 to 101.21This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)13592.44 ± 3686.1414155.46 ± 5300.06
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 98.01 · 90% CI 94.54 to 101.60This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryCmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Corrected Unconjugated Estradiol.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg/mL
Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
pg/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)55.18 ± 19.3156.24 ± 19.26
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.87 · 90% CI 93.22 to 102.74This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)1723.44 ± 540.761793.04 ± 689.12
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.96 · 90% CI 93.66 to 102.46This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)1823.43 ± 551.111871.56 ± 730.51
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 99.01 · 90% CI 94.17 to 104.11This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryCmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for Corrected Unconjugated Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg/mL
Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
pg/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)492.81 ± 166.57509.81 ± 217.80
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 99.13 · 90% CI 94.39 to 104.10This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for Corrected Unconjugated Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)10952.25 ± 3887.8411369.60 ± 5058.92
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.72 · 90% CI 94.03 to 101.56This analysis was for informational purposes only and was not used to establish bioequivalence.
SecondaryAUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)11293.21 ± 3899.1211747.97 ± 5289.05
Statistical analysis
  • Estradiol/Norethindrone Acetate (Test) vs Activella® (Reference) · Ratio of the t/r geometric mean x 100: 97.99 · 90% CI 94.11 to 102.02This analysis was for informational purposes only and was not used to establish bioequivalence.

Adverse events

Collected over Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estradiol/Norethindrone Acetate (Test)—0/40 (0%)1/40 (2.5%)
Activella® (Reference)—0/40 (0%)2/40 (5%)
Most frequent other events
Most frequent other events
EventEstradiol/Norethindrone Acetate (Test)Activella® (Reference)
HeadacheGeneral disorders1/402/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Estradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years202040
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Estradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) FirstTotal
Female202040
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Estradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) FirstTotal
Caucasian131528
Hispanic314
Black224
Asian213
American Indian011
Region of Enrollment
Region of Enrollment(participants)Estradiol/Norethindrone Acetate (Test) FirstActivella® (Reference) FirstTotal
Canada202040
08

Study locations

1 site
  • Biovail Contract Research
    Toronto, Ontario M1L 4S4, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2010
First posted
Aug 13, 2010
Start
Jan 2007
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results first posted
Oct 7, 2010
Last update
Dec 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01181726
First posted
Aug 13, 2010
Start date
Jan 2007
Primary completion
Feb 2007
Completion
Feb 2007
Results posted
Oct 7, 2010
Last update
Dec 8, 2010

Study contacts

Paul Y Tam, M.D., F.R.C.P., F.A.C.P.
principal investigator · Biovail Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Norethindrone Acetate

Start the discussion